Home Cart Sign in  
Chemical Structure| 3433-74-7 Chemical Structure| 3433-74-7

Structure of 3433-74-7

Chemical Structure| 3433-74-7

5,11-Dihydrodibenzo[b,e][1,4]oxazepine

CAS No.: 3433-74-7

4.5 *For Research Use Only !

Cat. No.: A242457 Purity: 97%

Change View

Size Price

US Stock

Global Stock

In Stock
100mg łóÿ¶ÊÊ Inquiry Inquiry
250mg łÇͧ¶ÊÊ Inquiry Inquiry
1g ł§óÿ¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 100mg

    łóÿ¶ÊÊ

  • 250mg

    łÇͧ¶ÊÊ

  • 1g

    ł§óÿ¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 3433-74-7 ]

CAS No. :3433-74-7
Formula : C13H11NO
M.W : 197.23
SMILES Code : C1OC2=C(NC3=C1C=CC=C3)C=CC=C2
MDL No. :MFCD04108301
InChI Key :SLGIBJWUMUWIFH-UHFFFAOYSA-N
Pubchem ID :11084798

Safety of [ 3433-74-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 3433-74-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 12
Fraction Csp3 0.08
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 63.46
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

21.26 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.21
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.01
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.79
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.56
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.92
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.7

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.55
Solubility 0.0554 mg/ml ; 0.000281 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.12
Solubility 0.149 mg/ml ; 0.000757 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.98
Solubility 0.00206 mg/ml ; 0.0000104 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.37 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.81

Application In Synthesis of [ 3433-74-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 3433-74-7 ]

[ 3433-74-7 ] Synthesis Path-Downstream   1~34

  • 1
  • [ 103-76-4 ]
  • [ 109-70-6 ]
  • [ 3433-74-7 ]
  • 2-{4-[3-(11<i>H</i>-dibenzo[<i>b</i>,<i>e</i>][1,4]oxazepin-5-yl)-propyl]-piperazin-1-yl}-ethanol [ No CAS ]
  • 2
  • [ 104-16-5 ]
  • [ 3433-74-7 ]
  • [ 101524-22-5 ]
  • 3
  • [ 108-24-7 ]
  • [ 3433-74-7 ]
  • [ 16882-85-2 ]
  • 4
  • [ 108-24-7 ]
  • [ 3433-74-7 ]
  • [ 28667-08-5 ]
  • 5
  • [ 100-39-0 ]
  • [ 3433-74-7 ]
  • [ 16882-86-3 ]
  • 6
  • [ 23349-86-2 ]
  • [ 3433-74-7 ]
  • [ 52694-38-9 ]
  • 7
  • [ 151-50-8 ]
  • [ 109-70-6 ]
  • [ 3433-74-7 ]
  • [ 60578-93-0 ]
  • 8
  • [ 109-70-6 ]
  • [ 3433-74-7 ]
  • [ 60578-92-9 ]
  • 9
  • [ 100-35-6 ]
  • [ 3433-74-7 ]
  • [2-(11<i>H</i>-dibenzo[<i>b</i>,<i>e</i>][1,4]oxazepin-5-yl)-ethyl]-diethyl-amine [ No CAS ]
  • 11
  • [ 104-77-8 ]
  • [ 3433-74-7 ]
  • [ 28889-19-2 ]
  • 12
  • [ 625-36-5 ]
  • [ 3433-74-7 ]
  • [ 97470-61-6 ]
  • 13
  • [ 75-44-5 ]
  • [ 3433-74-7 ]
  • [ 10386-68-2 ]
  • 14
  • [ 4172-04-7 ]
  • [ 3433-74-7 ]
  • [ 98284-11-8 ]
  • 15
  • [ 89583-17-5 ]
  • [ 3433-74-7 ]
  • <i>N</i>-[3-(11<i>H</i>-dibenzo[<i>b</i>,<i>e</i>][1,4]oxazepin-5-yl)-2-methyl-propyl]-<i>N</i>-methyl-formamide [ No CAS ]
  • 16
  • 3-bromo-1-<i>tert</i>-butyl-azetidine [ No CAS ]
  • [ 3433-74-7 ]
  • [ 69158-86-7 ]
  • 17
  • [ 3433-74-7 ]
  • [ 57529-60-9 ]
YieldReaction ConditionsOperation in experiment
4) An N,N-dimethylformamide (110 ml) solution of the compound (9.6 g) obtained in 3), potassium carbonate (8.7 g), and copper powder (710 mg) was stirred at 150 C. in a stream of argon air. After 3.5 hours, the mixture was filtered while it was still hot. The filtrate was washed with ethanol and concentrated under reduced pressure. The thus-obtained residue was dissolved in ethanol (80 ml) and treated with activated charcoal. After filtration, the filtrate was concentrated and dissolved in ethanol (80 ml). A 25% sodium hydroxide aqueous (17 ml) solution was added to the solution and heated under reflux for 1 hour with stirring. After the resulting reaction solution was concentrated under reduced pressure, water was added thereto, and the solution was extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The thus-obtained residue was purified by silica gel column chromatography (developing solvent, ethyl acetate:hexane=1:10) and recrystallized from hexane to obtain the desired compound (4.4 g; yield, 71%) as a white solid.
  • 20
  • 2-aminophenyl 2-chlorobenzyl ether [ No CAS ]
  • [ 3433-74-7 ]
  • 21
  • 2[(2-bromobenzyl)oxy]aniline hydrochloride [ No CAS ]
  • [ 3433-74-7 ]
  • 25
  • [ 3433-74-7 ]
  • [ 60578-97-4 ]
  • 27
  • [ 3433-74-7 ]
  • [ 60578-94-1 ]
  • 28
  • [ 3433-74-7 ]
  • [ 33199-86-9 ]
  • 29
  • [ 3433-74-7 ]
  • [ 33199-85-8 ]
  • 30
  • [ 3433-74-7 ]
  • [ 33199-82-5 ]
  • 31
  • [ 3433-74-7 ]
  • [ 33211-38-0 ]
  • 32
  • [ 3433-74-7 ]
  • [ 33211-30-2 ]
  • 34
  • [ 3433-74-7 ]
  • 11<i>H</i>-dibenzo[<i>b</i>,<i>e</i>][1,4]oxazepin-5-ylamine [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Parent Nucleus of
[ 3433-74-7 ]

Other Aromatic Heterocycles

Chemical Structure| 50548-43-1

A277146 [50548-43-1]

4-Dibenzofuranamine

Similarity: 0.77

Chemical Structure| 135-67-1

A129838 [135-67-1]

10H-Phenoxazine

Similarity: 0.74

Chemical Structure| 1058704-69-0

A151193 [1058704-69-0]

5-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine

Similarity: 0.74

Chemical Structure| 3693-22-9

A334844 [3693-22-9]

Dibenzo[b,d]furan-2-amine

Similarity: 0.72

Chemical Structure| 105679-22-9

A116061 [105679-22-9]

7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine

Similarity: 0.70